you are here: HomeNewsGilletteindia
management interviews
Jump to
14 Results Found
  • Do not require capex for next 3-4 years: Granules India Nov 10, 2017 03:34 PM IST

    Do not require capex for next 3-4 years: Granules India

    Granules India's second quarter earnings were more or less inline or a tad bit lower than what the street was working with but their overall performance has been largely in-line.

  • Portuguese Regulator clears Granules India's Gagillapur plant Feb 03, 2017 01:05 PM IST

    Portuguese Regulator clears Granules India's Gagillapur plant

    Granules India‘s Gagillapur Plant gets an all-clear certificate from Portuguese Regulator INFARMED post re-inspection done from January 31 to Feb 2.

  • Granules India to file 2 ANDAs in US, 4 here this year Oct 26, 2016 12:00 PM IST

    Granules India to file 2 ANDAs in US, 4 here this year

    Granules India is looking at expanding its business to new geographies. The company is targeting 30-40 percent bottomline growth in FY18, C Krishna Prasad, MD of company said.

  • Orange ibuprofen will help strengthen US portfolio: Granules Oct 13, 2016 04:38 PM IST

    Orange ibuprofen will help strengthen US portfolio: Granules

    Granules India gets US FDA approval for orange-coloured 200 mg version of ibuprofen. Speaking to CNBC-TV18, C Krishna Prasad said that the market for orange-coloured tablet is around USD 49 million.

  • Expect revenue growth in coming quarters: Granules India May 30, 2016 03:42 PM IST

    Expect revenue growth in coming quarters: Granules India

    In an interview with CNBC-TV18, C Krishna Prasad, MD of Granules India said that four domestic plants were inspected by USFDA and one plant is due for inspection soon.

  • Expect 15-20% revenue growth in FY17: Granules India Jan 29, 2016 10:54 AM IST

    Expect 15-20% revenue growth in FY17: Granules India

    C Krishna Prasad, MD of Granules India expects a 15 percent revenue growth in Q4 and 15-20 percent rise in FY17.

  • Targeting FY16 margins at 20%: Granules India Nov 24, 2015 02:56 PM IST

    Targeting FY16 margins at 20%: Granules India

    C Krishna Prasad, MD, Granules India says margins in contract research and manufacturing services (CRAMS) business is relatively high and expects 30-35 percent of capacity utilization in the same.

  • Ibuprofen to add USD 2-4 mn to revenue: Granules India Sep 28, 2015 12:48 PM IST

    Ibuprofen to add USD 2-4 mn to revenue: Granules India

    C Krishna Prasad, Managing Director (MD) of Granules India said with only three to four main competitors in the US market, the company‘s topline and bottomline will benefit from the drug.

  • See 20% revenue growth in FY16: Granules India Sep 11, 2015 03:44 PM IST

    See 20% revenue growth in FY16: Granules India

    C Krishna Prasad, MD, Granules India says the company has secured businesses from Wal-Mart and CVS and incremental benefits will come going forward.

  • Eye FDA approval for new plant; rev growth at 26%: Granules Jan 05, 2015 01:51 PM IST

    Eye FDA approval for new plant; rev growth at 26%: Granules

    Revenue growth for the global pharmaceutical company stands at 15 percent for FY15 and 25 percent for FY16. Going ahead, the company awaits FDA approval for their new plant, C Krishna Prasad adds.

  • Will reap benefits of Auctus deal in 3-4 yrs: Granules Nov 05, 2013 04:40 PM IST

    Will reap benefits of Auctus deal in 3-4 yrs: Granules

    Speaking to CNBC-TV18 on the acquisition of the Rs 100 crore company, C Krishna Prasad, managing director, Granules India, says the deal has been funded by a mix of accruals and debt.

  • Granules India expects to grow at 30% in FY14 Jul 25, 2013 04:19 PM IST

    Granules India expects to grow at 30% in FY14

    "We have expanded significantly over the last two years, our assets are yielding right now a lot of the profit is because of growth in revenue," Granules India executive director Harsha Chigurupati said elaborating reasons for strong growth.

  • Granules India expects 30% growth in FY14 Apr 26, 2013 05:41 PM IST

    Granules India expects 30% growth in FY14

    Harsha Chigurupati, director, Granules India, says that last year the company reported a major increase in profit due to forex gains of around Rs 8 crore. This year too, the company performed better than previous year. There has been improvement in revenues and the company expects revenues to grow at 30 percent in FY14.

  • Expecting a growth rate of 40% in FY12: Granules India Jan 25, 2012 03:34 PM IST

    Expecting a growth rate of 40% in FY12: Granules India

    C Krishna Prasad, MD, Granules India, spoke to CNBC-TV 18 about the company's performance and what to expect in the days to come.

Sections